NCT03071263
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
See it on ClinicalTrials.gov ↗295 people
48.1%
51.9%
142 womenmiddle line = equal numbers153 men
- Phase
- PHASE2
- Paid for by
- Relypsa, Inc.
- Finished
- 2018-11-27
- Health conditions
- Hyperkalemia, Resistant Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 68.1 years
- Age 65+
- 68.5%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 98.3% · Black / African American 1.4% · Not reported 0.3% · American Indian / Alaska Native 0% · Asian 0% · Native Hawaiian / Pacific Islander 0% · More than one race 0%
Women left out
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“History of untreated known causes of high blood pressure, excluding kidney disease (not CKD)”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Recent cardiovascular event with last 3 months”
- No cancer
Women with current or past cancer were turned away.
“History of cancer within past 12 months”
Study titles and rules are shown in their original English.